Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital sees upside at Bunzl ahead of H2 recovery

(Sharecast News) - Bunzl's share price was up 5% on Tuesday after a solid first-half report from the distribution company, with broker Shore Capital reiterating a 'buy' stance on the stock. Results for the six months to 30 June were slightly below estimates, with a 0.8% increase in revenues to £5.75bn missing Shore Capital's forecast by around 1% or £60m.

Underlying revenues were flat, while the EBIT margin fell 100 basis points over last year to 7.0%. However, "the problem areas in North America and higher costs in Europe are being addressed", said analyst Robin Speakman.

With the company set to resume its share buyback - "a sign of confidence", according to Speakman - Shore Capital maintained a positive view on the stock and kept its forecasts unchanged, with Bunzl's management guiding to a stronger second half.

"Bunzl's asset allocation commitment to create shareholder value remains unchanged, ensuring/leveraging financial strength. So, we expect to see the impact of the resilient business model delivering recovery through H2F, noting the free cash flow yield of still 7.1% for this year, rising to 9.2% for FY26F in our forecast model," the analyst said.

As for Bunzl's valuation, the stock is currently trading at an enterprise value-to-EBITDA multiple of 8.8, though Shore Capital's fair value estimate of 3,040p implies a 2026 EV/EBITDA of 9.9x.

By 1217 BST, the stock was up 5.1% at 2,506p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.